Re N Tox
Re N Tox is a botulinum toxin type A product manufactured by PharmaResearchBio, the toxin-focused subsidiary of PharmaResearch. It is a Korean product and export-market brand context, not a generic name for botulinum toxin or a substitute label for another manufacturer’s product.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Re N Tox |
| Toxin type | Botulinum toxin type A |
| Manufacturer | PharmaResearchBio |
| Parent company | PharmaResearch |
| Korean commercialization | PharmaResearch |
Presentation And Approval Context
Section titled “Presentation And Approval Context”PharmaResearchBio reported Korean approval for Re N Tox 100-unit in February 2024. PharmaResearch announced domestic sales of that presentation in April 2025, while an official English-language company announcement describes 100-unit and 200-unit presentations for export.
Korean approval and export presentation references do not establish the same approval, presentation, or availability in another market.
U.S. FDA Context
Section titled “U.S. FDA Context”U.S. online listings do not establish FDA approval. In a November 3, 2025 warning letter to the retailer Glow Nest Beauty 🔗, FDA identified products offered as “Rentox 200U” as unapproved. The letter concerns that retailer’s offerings; it is not a CRL for a PharmaResearchBio application or a determination about the authenticity of every product sold under a similar name.
Re N Tox’s Korean approval should therefore remain separate from the FDA-approved products and public U.S. application stages.
Parent Company And Manufacturer
Section titled “Parent Company And Manufacturer”PharmaResearch and PharmaResearchBio have related but different roles. PharmaResearch supplies the wider corporate and aesthetics-portfolio context; PharmaResearchBio is the toxin-manufacturing subsidiary. Preserving that distinction helps avoid treating a parent portfolio as proof of a product’s manufacturer, label, or approval holder.
Unit And Comparison Limits
Section titled “Unit And Comparison Limits”Re N Tox units are product-specific. They cannot be converted through a universal ratio to units of Botox, Dysport, Xeomin, Jeuveau, Daxxify, Letybo, or other type A products. Shared type A biology does not establish equivalent indications, formulation, safety, duration, or clinical outcomes.